Eisai’s Fycompa (perampanel) Injection Formulation Receives MHLW’s Marketing Authorization for Epilepsy
Shots:
- The sNDA for Fycompa, filed in Aug 2022, has been granted marketing authorization by the Japanese MHLW for the injection formulation, providing an alternative therapy when its oral administration is temporarily not possible
- The injection formulation of Fycompa will prevent the risk of seizure if oral administration is temporarily halted, like during surgery. Earlier it was available as a tablet and fine granule formulation
- Fycompa acts as a selective, noncompetitive AMPA receptor antagonist to reduce neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors
Ref: Eisai | Image: Eisai
Related News:- Catalyst to Acquire Commercial Rights of Eisai’s Fycompa (perampanel) CIII in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
